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Background: Pouchitis occurs in up to 50% of patients with ulcerative colitis (UC) 
undergoing Heal pouch anal anastomosis (IPAA). Pouchitis rarely occurs in patients with 
familial adenomatous polyposis (FAP) who undergo IPAA. Our aim was to compare mucosal 
and luminal flora in patients with UC-associated pouchitis (UCP), healthy UC pouches (HUC), 
and healthy FAP pouches (FAP). 
Methods: Nineteen patients were enrolled in this cross-sectional study (nine UCP, three HUC, 
seven FAP). Patients with active pouchitis were identified using the Pouchitis Disease 
Activity Index (PDAI). Heal pouch mucosal biopsies and fecal samples were analyzed with a 
16S rDNA-based terminal restriction fragment length polymorphism (TRFLP) approach. Pooled 
fecal DNA from four UCP and four FAP pouches were sequenced for further speciation. 
Results: TRFLP data revealed statistically significant differences in the mucosal and fecal 
microbiota between each group of patients. UCP samples exhibited significantly more TRFLP 
peaks matching Clostridium and Eubacterium genera compared to HUC and FAP pouches 
and fewer peaks matching Lactobacillus and Streptococcus genera compared to FAP. DNA 
Sanger sequencing of a subset of luminal samples revealed UCP having more identifiable 
sequences of Firmicutes (51.2% versus 21.2%) and Verrucomicrobia (20,2% versus 3,2%), and 
fewer Bacteroidetes (17,9% versus 60.5%) and Proteobacteria (9,8% versus 14,7%) compared to 
FAP. 
Conclusions: The pouch microbial environment appears to be distinctly different in the settings 
of UC pouchitis, healthy UC, and FAP. These findings suggest that a dysbiosis may exist in 
pouchitis which may be central to understanding the disease. 
Abdominal colectomy with ileal pouch anal anastomosis .(IPAA) is the preferred surgery for 
patients with ulcerative colitis (UC) unresponsive to medical therapy or with dysplasia and for 
those with familial adenomatous polyposis syndrome (FAP),I Inflammation of the ileal pouch, 
termed pouchitis, is the most common long-term complication in patients with UC who undergo 
IPAA.2 Pouchitis occurs in up to 50% of these patients3'4 and is the major factor leading to 
morbidity after IPAA surgery in patients with UC.3't In comparison to individuals with a history of 
UC, those undergoing IPAA for FAP are far less likely to develop pouchitis.5 
The pathogenesis of pouchitis is incompletely understood. Proposed etiologies include fecal 
stasis, bacterial overgrowth, dysbiosis, genetic susceptibility, short-chain fatty acid deficiency, 
ischemic complications of surgery, bile-acid toxicity, immune alteration, a missed diagnosis of 
Crohn's disease (CD), or a recurrence of UC in the pouch.1.6,1 Pouch bacteria appear central to the 
pathophysiology of the disease. The efficacy of antibiotics in ameliorating pouchitis underscores the 
role of mucosal or luminal bacteria in the development of pouchitis." The role of gut microbes in 
pouchitis is further supported by studies revealing fewer pouchitis relapses and postoperative 
prophylactic benefit with probiotic therapy.1° A therapeutic utility of both antibiotics and 
probiotics suggests there may be subtle shifts in pouch microflora that culminate in pouch 
inflammation. 
Recently, Komanduri et all' described a pouch dysbiosis in five patients with UC and pouchitis 
when compared to patients with UC and no pouchitis and to healthy ileal tissue in continuity with 
the colon. Inflamed pouch mucosa was found to have greater bacterial species diversity than pouch 
control or healthy ileal tissue. Fusobacterium varium was more abundant in pouchitis tissue, 
while Streptococcus species were dramatically reduced. Healthy UC pouches possessed a unique 
floral pattern, with more representatives from the Clostridium, Enteric, and Streptococcus groups 
compared to ileal tissue from healthy subjects. 
In our study we aimed to characterize both mucosal and luminal microflora in inflamed UC 
pouches compared to healthy UC and FAP pouches. We designed the study with FAP pouch 
control subjects in an effort to find shifts in flora that were distinct to UC and inflammation 
rather than fecal stasis. We utilized 16S ribosomal DNA gene-based terminal restriction fragment 
length polymorphism (TRFLP) techniques to characterize luminal and mucosal microbial 
environments, followed by DNA sequencing for further characterization and validation. 
MATERIALS AND METHODS 
Patient Population 
Individuals over age 18 years were enrolled from the Massachusetts General Hospital (MGH) 
Gastrointestinal Unit in one of three cohorts with pouches after IPAA: those with a history of 
UC and subsequent pouchitis (UC pouchitis, UCP), those with a history of UC without pouchitis 
(healthy UC pouch, HUC), or those with a history of FAP without pouchitis (healthy FAP pouch, 
FAP). The diagnosis of UC and FAP in these patients was based on standard clinical, radiologic, 
and histologic diagnostic criteria. UCP patients were eligible if they had experienced at least two 
episodes of antibiotic-responsive pouchitis symptoms in the previous 2 years or had persistent 
pouchitis symptoms despite two courses of antimicrobial therapy. A Pouch Disease Activity Index 
(PDAI, comprising clinical, endoscopic, and histologic elements) score >7 was required for 
inclusion in the UCP group.I2 Eligible UCP patients underwent colectomy with IPAA more than 
3 months prior to enrollment. Eligible HUC and FAP patients underwent colectomy with IPAA more 
than 1 year prior to enrollment without experiencing pouchitis symptoms. Exclusion criteria for each 
group included any indication of CD and the use of probiotics, biologic or other immunosuppressive 
therapy, rectal therapy, or new antibiotics during the previous 2 months. Chronic antibiotic use for 
more than 3 months was permitted in the UCP group if the patient's symptoms persisted without 
the use of new antibiotics. 
Data Collection 
Key clinical data collected from each patient included age, gender, disease duration and 
extent, pouch duration, number of pouchitis episodes in the previous year, medication use, and 
the clinical components of the PDAI. The PDAI clinical score takes into account stooling 
frequency and the presence of hematochezia, stooling urgency, abdominal cramping, and fever. 
Endoscopic and histologic findings were noted for each patient and incorporated into the PDAI 
score. 
Specimen Collection 
All patients underwent pouchoscopy after clinical data were collected. Patients received a 
short course of bowel preparation 1 day prior to the procedure with phospho-soda. Luminal pouch 
contents were suctioned through the colonoscope into a sterile container. Approximately I cc of 
the suctioned stool was aliquoted into each of three vials containing 1 cc of 10% glycero1/90% 
sterile water. Tubes were inverted to generate a homogeneous mixture then immediately placed 
in dry ice. The pouch was examined for elements of the PDAI endoscopic score: edema, 
granularity, friability, loss of vascular pattern, mucous exudates, and ulceration. Then three 
biopsies were taken at the most inflamed sites or at random locations from normal-appearing 
tissue. Each tissue specimen was immediately rinsed in normal saline then placed in a vial 
containing 1 cc of 10% glycerol/90% sterile water. The vials were inverted to submerge the tissue 
specimen then immediately placed in dry ice. All specimens were then stored at —80°C within 
30 minutes. 
TRFLP Analysis 
All stool and tissue specimens were analyzed by TRFLP at the Environmental 
Biotechnology Institute at California Polytechnic State University (CPSU). DNA was isolated 
using MoBio's Power Soil DNA extraction kit according to the manufacturer's protocol (MoBio 
Laboratories, Carlsbad, CA). Triplicate 0.1-g samples were used for the extraction of stool 
samples, while the entire biopsy sample was used for the isolation of DNA from tissue samples. 
Bacterial 16S ribosomal RNA genes were amplified from both types of sample using the 
forward primer 8DF (5'-AGA GTT TGT TCM TGG CTC AG-3') and the reverse primer 536-
K2R (5'-GTA TTA CCG CGG CTG CTG G-3'). The forward primer was fluorescently labeled 
with a phosphamide dye. Fifty microliter reactions were assembled using 1 FL of undiluted 
DNA, 5 pl., of 10x buffer, 3 pl. of 10 mM dNTPs, 2 tL of 20 mg/mL BSA, 7 pL of 25 mM 
MgCl2, 1 tL of each primer, and 0.3 ,td, of 5 U/L TaqGold (Applied Biosystems, Foster City, 
CA). 
Reaction temperatures and times were as follows: 95°C for 10 minutes followed by 30 cycles of 
95°C for 1 minute, 60°C for 1 minute, and 72°C for 2 minutes, followed by a final extension of 
72°C for 10 minutes. The quality of the extractions and polymerase chain reaction (PCR) reactions 
were confirmed using gel electrophoresis. PCR triplicates were combined during a PCR cleanup 
performed using MoBio's PCR Cleanup Kit following the manufacturer's protocol (MoBio 
Laboratories). PCR products were quantified using a FLX800 microplate fluorescence reader 
tuned to the labeling dye (Bio-Tek Instruments, Winooski, VT). 
Three enzyme digests were independently performed using cleaned-up PCR product and the 
restriction endonucleases HaeIH, Hpall, and Alul (New England Biolabs, Beverly, MA). Each 
40-1,tL digest included 75 ng DNA, 1 U enzyme, and 4 pi, buffer. Samples were digested for 
4 hours at 37°C and the enzyme was inactivated for 20 minutes at either 65°C (HpaII 
and Alul) or 80°C (Haell1). Resulting fragments were ethanol precipitated and resuspended in 20 
[IL formamide and 0.25 tL CEQ 600 basepair standard. Terminal restriction fragments were 
separated using capillary gel electrophoresis and profiles were obtained using a Beckman 
Coulter (Fullerton, CA) CEQ8000X DNA analysis system. 
Terminal restriction fragment lengths and relative peak areas were exported from the 
CEQ8000 into Excel (Microsoft, Seattle, WA). TRF data consists of peak sizes, which indicate the 
length of the DNA fragment in nucleotides, and the area under each peak, which provide a mea-
sure of abundance for each DNA fragment. Since the amount of DNA loaded on the capillary 
cannot be accurately controlled, the sum of the total peak area varies between TRF patterns. 
Therefore, peak areas are normalized by converting the value to parts per million to standardize 
the data for comparison." Peaks with an area less than 10,000 ppm (<1.0% of the total) were 
excluded from the analysis to reduce excess noise. Data from three independent restriction enzyme 
digests were included to reduce the incidence of distinct sequences with equivalent TRF lengths. 
TRF fragments determined to differ most between sample groups were compared to available 
GenBank (Bethesda, MD) sequences to tentatively identify potential bacterial populations. TRFLP 
data were analyzed for peaks that could be identified by database analysis as representing particular 
groups of organisms. 
16S Ribosomal DNA-based DNA Sequencing 
Four fecal samples from each of the UCP group and the FAP group were selected for 
sequencing analysis of pooled DNA. Samples with the greatest intersample similarities in TRF 
profiles (as determined with Bray—Curtis similarity indices) were selected in an effort to create 
the most uniform pooled specimens representative of each patient group. DNA from the 
samples was processed as detailed for TRF analysis, using full-length 16S PCR primers 
without fluorescent label, then sent to the Broad Institute (Cambridge, MA) for sequencing. 
Samples were cloned into the pCR2.1-TOPO vector and sequenced on an ABI3730 DNA sequencer. 
Sequences were trimmed using LUCY.14 Read pairs from each clone were then assembled 
using the following alignment-assisted assembly method implemented at the Broad Institute. A 
reference sequence for use as an alignment template for the read pairs was first selected from a 
core set of nonchimeric 16S rRNA sequences obtained from Greengenes.15 The core set 
reference sequence sharing the greatest number of matching k-mers with the aggregate k-mer set 
of both forward and reverse reads was selected. Forward and reverse reads were each aligned to 
the core reference sequence using Blast.I6 Aligned forward and reverse reads were then assembled 
based on the alignment with base quality scores used and preserved through assembly. 
For purposes of classification, only assembled sequences of greater than 1100 nucleotides 
were considered. Sequences were classified using a naïve Bayesian rRNA classifier." The 
classifier was trained on the Ribosomal Database Project core set, RDP10.I8 
Statistics 
Differences in patient characteristics were assessed using Fisher's Exact test for categorical 
variables and the Exact Kruskal—Wallis test for continuous variables. TRFLP datasets were 
transformed by taking the square root of the area under each peak to deemphasize large TRFLP 
peaks while still accounting for relative abundance. Transformed data from UCP, HUC, and FAP 
groups were compared using Bray—Curtis similarity, multidimensional scaling, and analysis of 
similarity (ANOSIM) (Primer E, Plymouth, UK). ANOSIM was also used to compare 
intersubject and intrasubject TRFLP profile similarities. Analysis of variance (ANOVA) was 
used to compare relative abundance of specific TRFLP pattern elements between each group of 
subjects. Among the pooled fecal DNA samples, differences in the percentage of total identifiable 
clones represented by each bacterial genus were calculated using Fisher's Exact test, 
considering that the number of identifiable clones in a sample is proportional to species 
abundance. 
Ethical Considerations 
This study was approved by the Institutional Review Boards at MGH and CPSU. 
[Insert Table 1] 
 
RESULTS 
Patients 
A total of 19 patients were enrolled and divided into three groups: UCP (n = 9), FAP (n 
=. 7), and HUC (n =- 3) (Table 1). Overall, 37% of patients were female and the average age was 
40.6 years. There were no significant differences in baseline demographics or disease characteristics 
between the three groups. PDAI values were significantly higher in the UCP group (P < 0.001). 
All mucosal biopsies in the UCP group displayed histologic evidence of active pouchitis. One UCP 
patient received chronic ciprofloxacin therapy for the prior 8 years and one received chronic 
rifaximin therapy for the prior year, both with continued episodes of pouchitis. Three UCP 
patients had received short courses of ciprofloxacin ranging from 3 months to 1 year prior to 
enrollment. The remaining four UCP patients received ciprofloxacin briefly —2 years prior to 
enrollment. 
TRFLP Analysis 
Significantly more peaks were observed in TRFLP data from mucosal samples (average total 
number of peaks/ sample in three digests = 64.8, standard deviation [SD] = 12.2) compared to fecal 
samples (average total number of peaks/sample in three digests = 41.3, SD = 8.2) with P < 0.001 
(Fig. 1). The greatest amount of similarity existed within samples from the same person, with 
both mucosal and fecal sample similarity greater within a subject than between subjects (P = 
0.027). There was no significant difference between patient groups in the degree of similarity 
between fecal and mucosal samples (P > 0.05). Between individuals, mucosal TRFLP profiles 
were found to be more consistent than fecal samples (P < 0.001). 
TRFLP data from mucosal and fecal samples were significantly different between each of 
the three patient groups. Figure 2 displays the results of multidimensional scaling analysis 
comparing TRFLP data. Significant differences (P < 0.05) in bacterial TRFLP data were 
revealed between the UCP group, HUC group, and FAP group when comparing mucosal samples, 
fecal samples, and when both sample types were combined. Samples from the two UCP patients 
receiving a single long-term antibiotic were not significantly different compared to other UCP 
samples. Samples from the three patients who received prior short courses of antibiotics within 1 
year were also not significantly different, as all nine UCP samples grouped together apart from 
HUC and FAP. 
Approximately 15% of the total number of TRFLP peaks were matched to peak sets in the 
database. In an analysis of TRFLP elements that represent bacterial genera, a set of TRFs 
matching Lactobacillus and Streptococcus (Hae 264-5, Hpa 97-9, Alu 76, 532) were present at 
higher relative abundance in both mucosal and fecal samples from FAP patients compared to UCP 
(ratio 5:1 in mucosa, 3:1 in stool). A second set of TRFLP peaks (Hae 272-4, Hpa 222-3, Alu 
440) matching Clostridium, Eubacteriurn and Roseburia genera were present at five times the 
relative abundance in stool from UCP patients compared to FAP patients. Fecal samples from 
HUC pouches also had fewer peaks matching Clostridium, Eubacterium, and Roseburia 
compared to UCP (ratio 1:15). HUC stool revealed fewer Escherichia, Streptococcus, and 
various sulfur-oxidizing bacteria (Hpa 496, Hae 205, Alu 74) at a ratio of 1:2 compared to UCP. 
Mucosal samples from HUC pouches revealed a similar smaller quantity of Escherichia, 
Streptococcus, and various sulfur-oxidizing bacteria compared to UCP (ratio 1:2). 
[Insert Figure 1 and Figure 2] 
DNA Sequencing 
In all, 2304 clones were processed for each pooled sample (4608 total clones). After data 
processing and analysis, good quality forward and reverse reads were identified with a reliable 
classification at the genus level (>80%). A total of 712 sequences were identified in the UCP 
pooled sample and 1015 in the FAP pooled sample. 
At the phylum level, the UCP pooled sample revealed significantly more Firmicutes 
and Verrucomicrobia (52% and 22% of clones, respectively) compared to the FAP group 
comprised of 19% Firmicutes and 3% Verrucomicrobia (P < 0.001 and P < 0.001, respectively). 
However, numbers of clones in the Bacteroidetes phylum were significantly higher in the FAP group 
(71% of clones) compared to UCP (20% of clones, P < 0.001). There were no significant 
differences between pooled samples among the Fusobacteria, Proteobacteria, and Actinobacteria 
phyla (Table 2). [Insert Table 2] 
Multiple bacterial genera within the class Clostridia were significantly more prominent in the 
UCP group compared to the FAP group (Table 3). Among Clostridia, the UCP group had more 
clones represented by the genera Roseburia (8% of clones in UCP versus near 0% in FAP, P < 
0.001), Lachnospiraceae Incertae Sedis (28% versus 10%, P < 0.001), Clostridium (9% versus 
1%, P < 0.001), Lachnospira (2% versus 0, P < 0.001), and Veillonella (3% versus near 0%, 
P < 0.001). The UCP pooled sample also had more clones from the genus Prevotella than the 
FAP group (6% versus 1%, P < 0.001). Finally, the UCP group revealed 22% of its pooled clones 
from the genus Akkermansia in the phylum Verrucomicrobia, compared to only 3% in FAP (P < 
0.001). 
Members of the genus Bacteroides predominated in the pooled fecal sample of the FAP 
group, with 678 of 1015 (67%) clones representing Bacteroides, compared to 99 of 712 (14%) 
in UCP (P < 0.001). Other genera that were statistically more prominent in the FAP group were 
Faecalibacterium in the family Ruminococcaceae (6% of clones in FAP, 0% in UCP, P < 
0.001), Parabacteroides (2% in FAP, 0% in UCP, P < 0.001), and Escherichia (2% in FAP, 
0% in UCP, P < 0.001). 
DISCUSSION 
The results of our study suggest that the pouch microbial environment is distinctly different 
between patients with UC-associated pouchitis and healthy UC or FAP pouches. Using 16S ribosomal 
gene-based TRFLP data, we identified significant differences in bacterial communities 
between all three patient cohorts in both stool and mucosa. These broad differences in TRFLP 
profiles were further explored using DNA sequencing. Sequencing revealed multiple statistically 
significant variations in specific bacterial genera between pooled fecal DNA from a subgroup of 
patients with UCP and a subgroup of patients with FAP. 
We report data that supports previously published work suggesting a dysbiosis is central to 
the development of pouchitis. The efficacy of both antibiotics and probiotics in ameliorating the 
symptoms of pouchitis underscores the theory that shifts in bacteria may be important in the gener-
ation and cessation of pouch inflammation."" However, few details are known about the precise 
bacterial populations in the pouch and the nature of the dysbiosis associated with pouchitis. 
Studies based on classic culturing techniques have suggested the presence of more anaerobes in 
pouch effluent compared to ileostomy effluent and that pouch fecal bacterial populations are 
similar to rectal flora.2022 A later study using similar stool culture techniques noted a greater 
number of facultative anaerobes in the inflamed pouch lumen compared to the noninflamed UC 
pouch or normal ileum.23 More recently, Duffy et a124 used culture-based techniques to show that 
sulfate-reducing bacteria were present in the stool of 8 of 10 healthy UC pouches but not in any 
of seven FAP pouches. 
Molecular techniques have been used to define the pouch microbiota more precisely. Falk et 
a125 used TRFLP to demonstrate that pouch mucosal species in two healthy UC pouches 
resembled those from the colon. However, populations of Clostridium perfringens in both 
patients were unique to the pouch. To our knowledge, only one study, by Komanduri et al,E I used 
molecular techniques to compare pouch microbiota between UC patients with and without 
pouchitis. Using length-heterogeneity PCR followed by sequencing, they concluded that 
inflamed pouch mucosa had greater species diversity and more Fusobacterium varium than 
healthy UC pouches or healthy deal tissue in continuity with the colon. Noninflamed UC pouches 
revealed more representatives from the Clostridium, enteric, and Streptococcus groups compared 
to pouchitis and healthy nonpouch Heal tissue. These differences between UC and health could 
be explained by the fact that the healthy ileal tissue was in continuity with the colon without 
fecal stasis. In each of these studies the healthy pouch control subjects suffered from UC, without 
any non-inflammatory bowel disease (IBD) pouch controls. 
Our study was designed to utilize molecular techniques to identify bacterial populations 
unique to inflamed or healthy UC pouches compared to a non-IBD pouch, keeping pouch fecal 
stasis as a consistent factor across all patient groups. This design and our findings differed from 
the results of Komanduri et al.1' We found no increase in Fusobacterium species among inflamed 
pouches and instead noted the largest numbers of Clostridium species in the UCP group. We 
also noted a unique reduction in Bacteroides in the inflamed pouch compared to FAP. Our 
findings suggest that a mucosal and luminal dysbiosis exists in pouchitis, not only when 
compared to the healthy UC pouch but also when compared to a non-IBD pouch. Additionally, 
healthy UC pouches differed significantly from FAP pouches. This suggests an alteration in 
ileal pouch microbiota that may be unique to the UC disease state, with or without inflammation. 
Our TRFLP results supported an overall increase in fecal Clostridium in UCP patients 
compared to FAP patients. This finding may be consistent with those of Falk et al.25 DNA 
sequencing confirmed our findings, with the genus Clostridium representing 9% of identifiable 
clones in the UCP pooled sample compared to only 1% in the pooled FAP sample. More broadly, 
the class Clostridia accounted for 53% of identifiable clones in the UCP group compared to 21% 
in the FAP group. The genus Eubacterium was also more prevalent in the UCP stool by TRFLP, but 
no known Eubacterium species were revealed by sequencing. This may be due to the 
difficulty of TRFLP to distinguish between Eubacterium and Clostridium species. The 
decrease in Lactobacillus and Streptococcus genera in UCP compared to FAP pouches also was 
not reflected in the sequencing data. However, this is not surprising since the number of clones 
identified as representing Lactobacillus and Streptococcus was less than 0.5% of the total 
identified. These disparities between TRFLP and sequencing results could be explained by 
our sampling only four patients from each group for sequencing. Importantly, TRFLP is best 
used to compare bacterial community structure between samples and is less precise than 
sequencing analysis for bacterial speciation.26 
Sequencing results revealed an overall decrease of the phylum Bacteroidetes in the 
inflamed pouch. This finding is consistent with multiple molecular surveys of intestinal microbiota 
in both CD and UC.27-3° Bacteroidetes play a key role in maintaining gut health, so it has been 
proposed that a relative reduction in this population may favor the development of inflammation.29 
Consistent with our TRFLP data, DNA sequencing also demonstrated a significant increase in 
clostridia in the inflamed pouch, namely among the genera Clostridium, Lachnospiraceae, and 
Rosehuria. While multiple studies have shown a relative decrease in clostridia species among 
patients with CD,30-32 our findings are consistent with previous work in UC revealing more 
clostridia in inflamed UC rectal mucosa compared to noninflamed mucosa.33 
While evidence to date supports a general shift in multiple species as being linked to the 
development of IBD, we note two particular genera that reflect specific theories of IBD 
pathogenesis. We found significantly greater numbers of the genus Roseburia among inflamed 
pouches compared to FAP pouches. Roseburia are flagellated commensal inhabitants of the colon. 
Flagellin have been shown to induce proinflammatory gene expression by activating Toll-like 
receptor 5 (TLR5), and patients with TLR5 polymorphisms and low levels of antiflagellin 
antibodies may be protected from developing CD.34-36 High levels of antiflagellin antibodies, 
specifically anti-CBirl antibodies to flagellin of Clostridium species, are present in 50% of CD 
patients, 6% of UC patients, and may be associated with the development of pouchitis.37'38 It is 
unknown whether Roseburia species may play a role in TLR5 activation leading to increased 
mucosal inflammation. Additionally, we found the mucin-degrading genus Akkermansia of the 
phylum Verrucomicrobia to be significantly more prevalent in pouchitis. Several theories exist 
regarding the role of mucin in the protection of intestinal epithelium in IBD, with mutations, 
alterations, and degradation of mucins being associated with CD and UC.39-42 A recent large-scale 
genome-wide association study revealed that a gene encoding for mucin proteins, MUC19, was 
mutated significantly more often in patients with CD.43 While the mucin-degrading 
Verrucomicrobia species and Akkermansia in particular have been identified within the human 
colon,44'45 there have been only two reports of DNA from these bacteria in patients with CD" and no 
previous reports of Verrucomicrobia in UC. 
This study has certain limitations. TRFLP is best used to compare bacterial community 
structure between cohorts and is not precise in identifying species. Thus, the results of TRFLP 
should be interpreted as suggestive of bacterial groups, rather than specific species, and emphasis 
should be placed on the separation between each group. The study may have found more 
differences between patient groups if the sample size had been larger. Nevertheless, we were able 
to identify statistically significant differences in TRFLP data and clone libraries between groups. 
Another limitation was the pooling of DNA into groups for DNA sequencing. Individual 
sequencing of each sample was limited due to expense. This may have led to an apparent 
difference in flora between groups if only one sample had a unique bacterial profile. However, we 
grouped samples with similar TRFLP data in an effort to minimize the chance of one sample 
skewing the analysis. Additionally, the use of antibiotics in UCP patients may have altered gut 
flora. However, TRFLP profiles were similar in all UCP patients and distinct compared to HUC 
and FAP, regardless of whether the subjects had received antibiotics chronically or briefly 1-2 
years before enrollment. This suggests that the dysbiosis may be unique to pouchitis and not a 
direct result of exposure to antibiotic medications. 
In conclusion, we identified differences in the pouch microbiome between the inflamed pouch in 
UC, the healthy pouch in UC, and the healthy pouch in FAP. These differences in bacterial 
populations were evident in stool and mucosa by TRFLP analysis. 16S rDNA sequencing 
revealed specific differences in luminal bacterial genera, with the pouchitis group having 
substantially fewer Bacteroidetes and more Clostridia compared to the healthy FAP group. These 
findings reinforce other surveys of the micro-biome in both UC and CD. Additionally, one genus 
with flagellated species and one genus with mucin-degrading species were more prevalent in the 
pouchitis group, thus raising TLR5 activation and mucin degradation as possible factors in the 
pathogenesis of pouchitis. These results suggest that a dysbiosis may exist in both the inflamed 
and noninflamed UC pouch which may be central to understanding UC. 
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TABLE 1. Patient Demographic   
and Disease Characteristics 
  
UCP (n=9) FAP (n=7) HUC (n=3) P-value 
Mean age in years (range) 32.2 (22-61) 45.5 (29-55) 39.3 (26-55) 0.15 
Gender M = 2 (22%) M = 4 (57%) M = 1 (33%) 0.48 
 F= 7 (78%) F= 3 (43%) F= 2 (67%)  
Mean duration of pouch in years 
 
5.9 (1.5-13) 8.7 (1.4-21) 12.3 (2-20) 0.51 
Mean duration of UC in years 
 
8.8 (2.5-14) n/a 14.7 (3-25) 0.31 
Mean PDAI score (range) 
*Statistically significant. UCP, UC 
  
8.8 (7-12) 
familial adenomatous 
 
0 
HUC, healthy 
 
1(1) <0.001* 
 
 
 
TRF length (nucleotides) 
FIGURE 1. Example of raw TRFLP data. TRFLP data (Hpa digest) from one patient 
(stool and mucosal samples) illustrating the difference in diversity made apparent by 
TRFLP. Each peak represents one or more taxonomic unit(s) of bacteria defined by the 
single TRF length. Note the increased number of peaks in the mucosal sample. 
 
FIGURE 2. Multidimensional scaling (MDS) analysis of TRFLP data. MDS analysis compares 
complex profiles, here TRFLP peaks, in two-dimensional space with the most similar profiles 
being closest spatially and those most dissimilar being farthest apart. Each shape represents one 
patient's TRFLP profile. Differences between groups were evaluated using ANOSIM. P-values for 
each comparison are listed. 
 
 
 
